Developing novel blood‐based biomarkers for Alzheimer's disease

Abstract

Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey

“…One of these biofluids is the CSF, which is a clear fluid that surrounds the brain and spinal cord mainly for protection. CSF must be obtained by lumbar puncture [61].…”

“…Blood samples can be obtained in a less intrusive and less costly way [61] and more frequently than CSF samples, and thus, AD biomarkers on blood have also been searched. More precisely, the blood components plasma and serum have been analysed, as well as platelets [70].…”

“…Hanson et al [72] state that whether plasma Aˇ concentrations reflect Aˇ metabolism in the brain is very unclear and others affirm there is no relation at all [76]. Consequently, blood-based biomarkers of AD have not been still accepted due to the "failure to replicate findings" [61] and to the ambiguous results obtained in different studies. Nevertheless, it would be interesting to research further because blood can be easily obtained in routine tests.…”

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

“…CSF-based biomarkers are already being employed to identify at-risk patients and to improve the design of both epidemiological studies and clinical trials. 123 New PET radioligands, such as amyloid-labelling agents (three of which are now FDA-approved), can be used both diagnostically and to improve neuropathology-based patient stratification for clinical trials. Several tau imaging agents are also in human trials, and their utility in tauopathies, including CTE, is rapidly being established.…”

Amary llidaceae Perspectives In Alzheimer´S Disease

“…These findings emphasize the enormous and urgent need for develop an effective treatments [44]. Due to the complexity of the disease and increasing of population with advanced age, AD is the public health crisis of the 21 st century [45] and the current pharmacological therapies provide symptomatic improvement alone. Currently the drugs approved for the treatment of AD are classified into two groups: ACHEIs and N-Methyl-D-aspartate (NMDA) receptors [46].…”